Stem-Loop VEGF-A Aptamers for Multi-Isoform Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing aptamers struggle to target multiple isoforms and variants of vascular endothelial growth factor-A (VEGF-A) with high specificity and potency, failing to effectively inhibit its activity in various ocular diseases and disorders.
Innovation Solution
Development of aptamers with specific stem-loop secondary structures that bind to and inhibit VEGF-A121 and VEGF-A110, featuring consensus nucleic acid sequences and modifications to enhance binding affinity and specificity, including C-5 modified pyrimidines and sugar-modified nucleotides, which can inhibit VEGF-A variants with high potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional aptamers are used to target VEGF-A, then they can bind to some VEGF-A variants, but they fail to target multiple isoforms and variants with high specificity and potency
Solution Approach 1:
The patent designs aptamers with stem-loop secondary structures that can universally bind to multiple VEGF-A isoforms (VEGF-A121, VEGF-A110, and other variants) through conserved binding regions in the stem-loop structure, while the loop region provides variant-specific recognition, achieving both broad adaptability and high specificity simultaneously
Solution Approach 2:
The aptamer structure is divided into functional regions: the stem provides structural stability and the loop region provides specific binding recognition. This local differentiation allows the aptamer to maintain high specificity for different VEGF-A variants while preserving overall binding potency across multiple isoforms
2Reliability
If aptamers are designed with high specificity for multiple VEGF-A variants, then binding potency increases, but the complexity of aptamer design and characterization increases
Solution Approach 1:
The aptamer is segmented into distinct functional modules: a stem region (providing structural framework) and a loop region (providing binding specificity). This segmentation simplifies the design process by allowing independent optimization of each region for different VEGF-A variants while maintaining overall aptamer functionality
Solution Approach 2:
The patent systematically varies key parameters of the stem-loop structure (stem length, loop sequence, base pairing patterns) to optimize binding affinity and specificity for different VEGF-A variants, enabling high potency across multiple isoforms through controlled parameter adjustment rather than complete redesign
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers demonstrate strong binding and inhibitory effects on VEGF-A isoforms with IC50 values below 50 nM, effectively reducing VEGF-A-induced angiogenesis and KDR phosphorylation, making them suitable for treating ocular diseases.
Implementation Method 1
the aptamer comprises a stem-loop secondary structure which specifically binds to and inhibits at least one of VEGF-A121 and VEGF-A110
Data Source
AI summary
The application discloses methods and compositions for inhibiting functions associated with vascular endothelial growth factor-A (VEGF-A). The methods and compositions may involve the use of pan-variant specific aptamers for binding to VEGF-A, and preventing or reducing association of VEGF-A with Flt-1, KDR, or Nrp-1. The methods and compositions may include one or more aptamers that bind to receptor binding face of VEGF-A. The methods and compositions may include one or more aptamers that bind to a receptor binding domain of VEGF-A. The application further provides anti-VEGF-A aptamers for the treatment of ocular diseases or disorders. In some cases, the anti-VEGF-A aptamers may have a stem-loop secondary structure.